Share Favorites

Who to Treat


On September 10, 2013, Metamark announced positive results from a large clinical validation study of ProMarkTM, its biopsy-based prostate cancer prognostic test. The study, conducted in collaboration with Fred Saad, MD, FRCS, Professor and Chief, Division of Urology, Director of Urologic Oncology, University of Montreal Hospital Center, met its primary endpoint demonstrating that ProMarkTM, evaluated in standard formalin-fixed, paraffin-embedded prostate tissue, can differentiate indolent from aggressive disease.

ProMark Logo